Evidence map›Paper›PMID 32820363›Full record

ArticleEuropean journal of clinical pharmacology2021

A systematic approach for introduction of novel treatments to a chronic patient group: sacubitril-valsartan as a case study.

Helena Norberg, Ellinor Bergdahl, Karin Hellström Ängerud, Krister Lindmark

Abstract read
In one paragraph

Article in European journal of clinical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Helena NorbergDepartment of Public Health and Clinical Medicine, Umeå University, S-901 87, Umeå, Sweden.
Ellinor BergdahlDepartment of Public Health and Clinical Medicine, Umeå University, S-901 87, Umeå, Sweden.
Karin Hellström ÄngerudDepartment of Nursing, Umeå University, Umeå, Sweden.
Krister LindmarkDepartment of Public Health and Clinical Medicine, Umeå University, S-901 87, Umeå, Sweden. krister.lindmark@umu.se.ORCID http://orcid.org/0000-0002-5756-7791

Funding

The 1,6 Million Club -The Heart Foundation of Northern Sweden -
6 · The paper itself

Abstract

purposeTo develop a model for systematic introduction and to test the feasibility in a chronic disease population. We also investigated how the approach was received by the patients. METHODS AND

resultsThe systematic introduction approach is a seven-step procedure: step 1, define a few main criteria; step 2, primary scan patients with the one or two main criteria using computerized medical records/databases/clinical registries; step 3, identify patients applying the other predefined criteria; step 4, evaluate if any examinations/laboratory test updates are required; step 5, summon identified patients to the clinic with an information letter; step 6, discuss treatment with the patient and prescribe if appropriate; and step 7, follow up on initiated therapy and evaluate the applied process. The model was tested in a case study during introduction of the new drug sacubitril-valsartan in a heart failure population. In total, 76 out of 1924 patients were identified to be eligible for sacubitril-valsartan and summoned to the clinic to discuss treatment. Patient experiences with the approach were investigated in an interview study with general inductive approach using qualitative content analysis. This resulted in three final categories: a good approach, role of the information letter, and trust in care.

conclusionsThe systematic introduction approach ensures that strict criteria are used in the selection process and that a treatment can be implemented in eligible patients within a specified population with limited resources and time. The model was effective in our case study and maintained the patient's confidence in healthcare.

Indexed as

Medication Therapy ManagementModels, TheoreticalAminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsChronic DiseaseDrug CombinationsDrug SubstitutionFemaleHeart FailureHumansMaleValsartanAminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug Combinationssacubitril and valsartan sodium hydrate drug combinationValsartanChronic disease managementHealthcare quality improvementSacubitril-valsartanSystematic implementation

Identifiers

PMID32820363
PMCPMC7782406

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.